Please assess the completion status of the following clinical trial:

Trial Title: Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* The subject is a recipient of a living donor or deceased donor kidney transplant.~* Male or Female, 18 or older~Exclusion Criteria:~* First time recipient, PRA \>- 50% or for retransplantation PRA \>- 30%.~* If retransplantation, previous graft loss cannot be due to acute rejection.~* Positive cross match.~* Subject receiving extended criteria donor (ECD) organ~* For Long-term extension study-Subjects who have completed three years of study treatment (through Week 156)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cyclosporine (CsA) (Type: ACTIVE_COMPARATOR): None
- Belatacept LI (less intensive) (Type: EXPERIMENTAL): None
- Belatacept MI (more intensive) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).